The Russian Direct Investment Fund (RDIF) is open for joint research in India of the Sputnik V and Covishield vaccines developed by the British-Swedish company AstraZeneca, head of RDIF Kirill Dmitriev told a briefing on Tuesday.
"The developers of Sputnik V vaccine were the first to offer a joint research with AstraZeneca. These studies are now being completed in Azerbaijan and a number of other countries. We are still open to such open collaborative research with the Covishield vaccine in India. We believe the results can be tremendous," TASS quoted him as saying.
Dmitriev also said that joint studies of the Sputnik V and AstraZeneca combined vaccine are in their final stages and the first results will be published at the end of July. Earlier, the head of the RDIF reported that trials of the vaccine combining Astrazeneca and Sputnik V did not reveal the undesirable effects that were previously occasionally observed in the Oxford drug.